Serum CK-BB as a tumor marker in patients with carcinoma confirmed histologically.
We determined serum CK-BB mass concentration using a specific RIA method, in 267 patients with carcinoma confirmed histologically distributed as follows: 46 prostatic adenocarcinoma, 52 lung neoplasies, 70 colon carcinoma, 52 breast carcinoma and 41 gastric carcinoma; and also in 135 patients with histologically proved non-neoplastic diseases distributed as follows: 28 prostatic hyperplasy, 31 lung tuberculosis, 29 inflammatory bowel disease, 27 fibrocystic mastopathy and 20 gastroduodenal ulcer. Reference values in healthy subjects (n = 360) were 5.46 +/- 2.68 (SD) ng/ml. We found that serum CK-BB mass concentration is not a specific tumor marker but it is a valuable indicator of responsing to therapy and metastatic widespread. However, in prostatic carcinoma--prevalence 0.25, predictive positive value (PPV) 0.51 and predictive negative value (PNV) 0.88--and breast carcinoma--prevalence 0.32, PPV 0.60 and PNV 0.87--serum CK-BB can be used as a tumor marker. Only 12 over 268 patients with different neoplastic disease (4.47%) showed detectable serum CK-BB catalytic concentrations.
Arenas
J
J
Servicio de Bioquímica, Hospital 12 de Octubre, Madrid, Spain.
Diaz
A E
AE
Alcaide
M J
MJ
Santos
I
I
Martínez
A
A
Culebras
J M
JM
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood; D003110:Colonic Neoplasms / Q000097:blood; D003402:Creatine Kinase / Q000097:blood*; D005348:Fibrocystic Breast Disease / Q000097:blood; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood; D007527:Isoenzymes; D008175:Lung Neoplasms / Q000097:blood; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood; D013274:Stomach Neoplasms / Q000097:blood; D014397:Tuberculosis, Pulmonary / Q000097:blood
D014408:Biomarkers, Tumor; D007527:Isoenzymes; D003402:Creatine Kinase